Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00557193 · OUTCOME

Pharmacodynamics PIA Levels in Infants Given Lestaurtinib at DL2 in Combination With Chemotherapy

Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia · Source last updated 2024-07-15

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
Activity percentage
Interval / dispersion
Standard Deviation
Time frame
Sampled between weeks 6-12 from start of induction

What was measured

Summarized with mean and standard deviation for those with available data in Arm C

Analysis population: Arm C Dose Level 2 (DL2) patients who had data available for analysis.

Groups in this outcome

Arm C (Safety/Efficacy Dose Level 2)

Arm C (Safety and Efficacy), IR/HR MLL-R chemotherapy and lestaurtinib at DL2 (HR: 4.25 mg/kg/day; SR: 5 mg/kg/day)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Arm C (Safety/Efficacy Dose Level 2)63

Reported measurements

Source class 1
Values in Activity percentage · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Arm C (Safety/Efficacy Dose Level 2)69.0022.96Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        22.96
        value
        69.00
denoms
  1. counts
    1. group Id
      OG000
      value
      63
    units
    Participants
description
Summarized with mean and standard deviation for those with available data in Arm C
dispersion Type
Standard Deviation
groups
  1. description
    Arm C (Safety and Efficacy), IR/HR MLL-R chemotherapy and lestaurtinib at DL2 (HR: 4.25 mg/kg/day; SR: 5 mg/kg/day)
    id
    OG000
    title
    Arm C (Safety/Efficacy Dose Level 2)
param Type
MEAN
population Description
Arm C Dose Level 2 (DL2) patients who had data available for analysis.
reporting Status
POSTED
time Frame
Sampled between weeks 6-12 from start of induction
title
Pharmacodynamics PIA Levels in Infants Given Lestaurtinib at DL2 in Combination With Chemotherapy
type
SECONDARY
unit Of Measure
Activity percentage

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice